Navigation Links
Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
Date:11/11/2009

BROOMFIELD, Colo., Nov. 11 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today that it will present at Lazard Capital Markets 6th Annual Healthcare Conference November 17-18, 2009 at the St. Regis Hotel in New York.

Steve Orndorff, Ph.D., founder, president and CEO, will provide a corporate overview of Accera and an update on Axona(TM) on Tuesday, November 17 at 4:10 p.m. EST. A breakout session will follow Dr. Orndorff's presentation where he will be available for questions and answers.

About Axona(TM)

Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.

About Accera, Inc.

Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. Accera engages in research, development and commercialization of other clinical applications for Axona, and has a wholly owned subsidiary, Neuera Pharmaceuticals, with a pipeline of small molecule drugs for neurodegenerative diseases.

For more information about Accera, please visit www.accerapharma.com.

    Contacts:
    Accera, Inc.
    Steve Orndorff, Ph.D.
    President and CEO
    sorndorff@accerapharma.com

    Tiberend Strategic Advisors, Inc.
    (212) 827-0020
    Andrew Mielach
    amielach@tiberendstrategicadvisors.com

    or

    Farrell Denby
    fdenby@tiberendstrategicadvisors.com

SOURCE Accera, Inc.


'/>"/>
SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
2. CryoLife to Present at Upcoming Investor Conferences in New York
3. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
4. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
5. MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
6. VIVUS to Present at Lazard Capital Markets Healthcare Conference
7. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
8. Thoratec Presentation at Canaccord Adams Conference to be Webcast
9. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
10. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
11. Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017 On March 28, the U.S. ... adult patients with relapsing forms of multiple sclerosis (MS) ... first drug approved by the FDA for PPMS. Ocrevus ... professional.  "Multiple sclerosis can have a ... Dunn , M.D., director of the Division of Neurology ...
(Date:3/29/2017)... March 29, 2017 FinancialBuzz.com News Commentary  ... The U.S. could see ... a new report published by New Frontier Data, the legal cannabis ... pace of cannabis legalization in the United States ... considered to be a major factor that drives growth in this ...
(Date:3/28/2017)... YORK , March 28, 2017 "Chemotherapy Induced Neutropenia ... overview of the disease and global market trends of the Chemotherapy ... States , Europe ( France ... , Spain , UK) and Japan ... (RoE) and rest of the world (RoW). The ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is ... Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating ... Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, ... public to take the Diabetes Risk Test to find out if they are at ... World Airports will light up the evening sky by programming the LAX pylons the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, property values, ... leader in the real estate valuation industry for more than 40 years. , ...
(Date:3/28/2017)... ... March 29, 2017 , ... ... thyroid pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on ... answering common questions regarding thyroid function. , Dr. Izabella Wentz is a ...
(Date:3/28/2017)... ... 28, 2017 , ... Medforce Technologies, Inc., a leading provider ... has joined the National Association for Home Care and Hospice (NAHC), the largest ... dying Americans of all ages and the caregiver who provide them with in-home ...
Breaking Medicine News(10 mins):